Results 51 to 60 of about 1,651 (200)

A route for polonium 210 production from alpha-particle irradiated bismuth-209 target [PDF]

, 2014
A method is proposed for production of polonium-210 via the 209Bi(α, 3n)210At nuclear reaction. Bombardment of a bismuth-209 target was performed with a 37 MeV alpha-particle beam that leads to the production of astatine-210 (T1/2 = 8.1 h), which decays ...
Alliot, Cyrille, Champion, Julie, Deniaud, David, Haddad, Ferid, Mokili, Marcel, Montavon, Gilles,, Younes, Ali   +6 more
core   +4 more sources

Initial Investigations into Nanobody Functionalization and Radiolabeling with Astatine-211

Nuclear Medicine and Biology
Uma Maheshwari Bharathi, Arthur Soares Souza, Matthias M. Herth, Umberto Maria Battisti, Nicholas L. Fletcher, David J. Owen, Pie Huda, Andreas I. Jensen   +7 more
openalex   +2 more sources

Batch Studies for the Advancement of the Chromatographic Separation of Astatine-211 [PDF]

, 2023
Astatine, the least abundant naturally occurring element on earth, has attracted interest due to its unique fundamental chemistry and its potential use as an agent in targeted alpha therapy for cancer treatment.
Green, Brooklyn D
core  

Theoretical Inspecting of 211At Radionuclide via Coupled-Channel Model for Fusion Reaction of Stable Nuclei

Atom Indonesia, 2021
This work has been carried out to obtain and inspect of 211At radionuclide through fusion reaction. Cross-sections for fusion reaction have been calculated with different interaction combinations and excitations for 19F + 192Os and 18O + 193Ir reactions.
Z. M. Cinan, T. Başkan, B. Erol, A. H. Yılmaz   +3 more
doaj   +1 more source

Alpha‐emitters and targeted alpha therapy in cancer treatment

iRADIOLOGY, 2023
Alpha emitters are radionuclides with good pharmacological characteristics for the treatment of cancer because they decay by emitting high linear energy transfer particles.
Jiajia Zhang, Shanshan Qin, Mengdie Yang, Xiaoyi Zhang, Shenghong Zhang, Fei Yu   +5 more
doaj   +1 more source

Successful radioimmunotherapy of established syngeneic rat colon carcinoma with 211At-mAb. [PDF]

, 2013
Most carcinomas are prone to metastasize despite successful treatment of the primary tumor. One way to address this clinical challenge may be targeted therapy with α-emitting radionuclides such as astatine-211 (211At).
Bäck, Tom, Elgström, Erika, Eriksson, Sophie, Jensen, Holger, Lindegren, Sture, Nilsson, Rune, Tennvall, Jan   +6 more
core   +1 more source

Theoretical study in comparison of astatine adsorptions on metal carrier materials for targeted alpha therapy applications

Next Nanotechnology
Targeted Alpha Therapy treatments using astatine-211 (211At) is being studied as a promising method for cancer treatment, and gold nanoparticles have been studied as one of the promising carriers to deliver astatine to the target area.
Jeffrey Tanudji, Hideaki Kasai, Michio Okada, Hiroshi Nakanishi   +3 more
doaj   +1 more source

COST Action CA19114, Network for Optimized Astatine labelled Radiopharmaceuticals [PDF]

, 2020
Cancer is a major health concerns for European citizens. Thus, the main research aim of this Network for Optimized Astatine labeled Radiopharmaceuticals (NOAR) COST Action is to successfully demonstrate that one of the most promising radionuclides for ...
Abrunhosa, Antero, Albertsson, Per, Alves, Francisco, Aneheim, Emma, Apostolova, Paulina, Bouziotis, Penelope, Chicharo de Freitas, Jose Reinaldo, Cinan, Zehra Merve, Cleeren, Frederik, Corredoira Silva, Eva, D'Huyvetter, Matthias, D'Onofrio, Alice, Darkovska Serafinivska, Marija, De Jong, Marion, Drakalska, Elena, Faraggi, David, Garcia-Arguello, Segundo Francisco, Garnuszek, Piotr, Gaschet, Joelle, Gestin, Jean-François, Guerard, Francois, Haddad, Ferid, Henriksen, Gjermund, Herth, Matthias, Ingemann Jensen, Andreas, Janevik-Ivanovska, Emilija, Janković, Drina, Jensen, Holger, Kolenc Peitl, Petra, Kraeber-Bodéré, Françoise, Krošelj, Marko, Lindegren, Sture, Luque, Luis Alejo, Manda, Gina, Mikolajczak, Renata, Milaković, Dragana, Mitrovic, Nebojsa, Navarro, Laurent, Niculae, Dana, Palm, Stig, Popovtzer, Rachela, Pruszynski, Marek, Radu, Mihai, Rajkovača, Zvezdana, Rocha Paulo, António, Rösch, Frank, Rösch, Uwe, Seimbille, Yann, Stanković, Aljoša, Sönmez, Bircan, Tsoukalas, Charalampos, Vranjes Djuric, Sanja   +51 more
core  

A Solid-State Support for Separating Astatine-211 from Bismuth

Inorganic Chemistry, 2020
Increasing access to the short-lived α-emitting radionuclide astatine-211 (211At) has the potential to advance targeted α-therapeutic treatment of disease and to solve challenges facing the medical community. For example, there are numerous technical needs associated with advancing the use of 211At in targeted α-therapy, e.g., improving 211At chelates,
David H. Woen, Cecilia Eiroa-Lledo, Andrew C. Akin, Nickolas H. Anderson, Kevin T. Bennett, Eva R. Birnbaum, Anastasia V. Blake, Mark Brugh, Elodie Dalodière, Eric F. Dorman, Maryline G. Ferrier, Donald K. Hamlin, Stosh A. Kozimor, Yawen Li, Laura M. Lilley, Veronika Mocko, Sara L. Thiemann, D. Scott Wilbur, Frankie D. White   +18 more
openaire   +3 more sources

Evaluation of therapeutic efficacy of 211At-labeled farletuzumab in an intraperitoneal mouse model of disseminated ovarian cancer

Translational Oncology, 2021
Introduction: Antibodies labeled with alpha-emitter astatine-211 have previously shown effective in intraperitoneal (i.p.) treatments of ovarian cancer. In the present work we explore the use of investigational farletuzumab, aimed at the folate receptor ...
Stig Palm, Tom Bäck, Emma Aneheim, Andreas Hallqvist, Ragnar Hultborn, Lars Jacobsson, Holger Jensen, Sture Lindegren, Per Albertsson   +8 more
doaj   +1 more source